PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
67.50
+2.95 (4.57%)
At close: Feb 11, 2026
Market Cap26.40B
Revenue (ttm)n/a
Net Income-242.62M
EPS-0.66
Shares Out391.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume158,500
Average Volume230,460
Open64.50
Previous Close64.55
Day's Range64.40 - 68.00
52-Week Range8.68 - 77.00
Betan/a
RSI54.36
Earnings DateMay 18, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-... [Read more]

Sector Materials
Founded 2008
Employees 58
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements